SEC Form 4 filed by See Explanation of Responses Bvf Partners L P/Il

6/13/25 6:23:00 PM ET

$OLMA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $OLMA alert in real time by email

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BVF PARTNERS L P/IL

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Explanation of Responses

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock, $0.0001 par value⁽¹⁾								2,655,977	D⁽²⁾
Common stock, $0.0001 par value⁽¹⁾								2,003,966	D⁽³⁾
Common stock, $0.0001 par value⁽¹⁾								347,970	D⁽⁴⁾
Common stock, $0.0001 par value⁽¹⁾								99,556	I⁽⁵⁾	See footnote⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to buy)⁽⁷⁾	$4.08	06/11/2025		A		24,150		⁽⁹⁾	06/11/2035	Common stock, $0.0001 par value	24,150	$0	24,150	I⁽⁷⁾	See footnote⁽⁷⁾
Pre-Funded Warrant	$0.0001							⁽⁶⁾	⁽⁶⁾	Common stock, $0.0001 par value⁽¹⁾	3,291,004		3,291,004	D⁽²⁾
Pre-Funded Warrant	$0.0001							⁽⁶⁾	⁽⁶⁾	Common stock, $0.0001 par value⁽¹⁾	2,627,590		2,627,590	D⁽³⁾
Pre-Funded Warrant	$0.0001							⁽⁶⁾	⁽⁶⁾	Common stock, $0.0001 par value⁽¹⁾	336,288		336,288	D⁽⁴⁾
Stock Option (Right to buy)⁽⁷⁾	$12.36							⁽⁸⁾	06/14/2034	Common stock, $0.0001 par value	23,000		23,000	I⁽⁷⁾	See footnote⁽⁷⁾
Stock Option (Right to buy)⁽⁷⁾	$7.84							⁽⁸⁾	06/15/2033	Common stock, $0.0001 par value	21,520		21,520	I⁽⁷⁾	See footnote⁽⁷⁾
Stock Option (Right to buy)⁽⁷⁾	$3.61							⁽⁸⁾	06/16/2032	Common stock, $0.0001 par value	21,520		21,520	I⁽⁷⁾	See footnote⁽⁷⁾
Stock Option (Right to buy)⁽⁷⁾	$27.66							⁽⁸⁾	06/08/2031	Common stock, $0.0001 par value	21,520		21,520	I⁽⁷⁾	See footnote⁽⁷⁾
Stock Option (Right to buy)⁽⁷⁾	$19							⁽⁸⁾	11/17/2030	Common stock, $0.0001 par value	21,520		21,520	I⁽⁷⁾	See footnote⁽⁷⁾
Stock Option (Right to buy)⁽⁷⁾	$19							⁽⁸⁾	11/17/2030	Common stock, $0.0001 par value	21,520		21,520	I⁽⁷⁾	See footnote⁽⁷⁾
Stock Option (Right to buy)⁽⁷⁾	$19							⁽⁸⁾	11/17/2030	Common stock, $0.0001 par value	21,520		21,520	I⁽⁷⁾	See footnote⁽⁷⁾

1. Name and Address of Reporting Person^*

BVF PARTNERS L P/IL

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Explanation of Responses

1. Name and Address of Reporting Person^*

BIOTECHNOLOGY VALUE FUND L P

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Explanation of Responses

1. Name and Address of Reporting Person^*

BVF I GP LLC

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Explanation of Responses

1. Name and Address of Reporting Person^*

BIOTECHNOLOGY VALUE FUND II LP

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Explanation of Responses

1. Name and Address of Reporting Person^*

BVF II GP LLC

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Explanation of Responses

1. Name and Address of Reporting Person^*

Biotechnology Value Trading Fund OS LP

(Last)

(First)

(Middle)

P.O. BOX 309 UGLAND HOUSE

(Street)

GRAND CAYMAN

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Explanation of Responses

1. Name and Address of Reporting Person^*

BVF Partners OS Ltd.

(Last)

(First)

(Middle)

P.O. BOX 309 UGLAND HOUSE

(Street)

GRAND CAYMAN

KY1-1104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Explanation of Responses

1. Name and Address of Reporting Person^*

BVF GP HOLDINGS LLC

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Explanation of Responses

1. Name and Address of Reporting Person^*

BVF INC/IL

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Explanation of Responses

1. Name and Address of Reporting Person^*

LAMPERT MARK N

(Last)

(First)

(Middle)

44 MONTGOMERY ST.

40TH FLOOR

(Street)

SAN FRANCISCO

94104

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Explanation of Responses

Explanation of Responses:

1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

5. Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account.

6. Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise.

7. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

8. The shares subject to the option have fully vested.

9. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to Dr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Dr. Hrustanovic's continuous service through such vesting date.

Remarks:

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a member of Partners, Gorjan Hrustanovic, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners.

	BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	06/13/2025
	Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer	06/13/2025
	BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	06/13/2025
	Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer	06/13/2025
	BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	06/13/2025
	BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	06/13/2025
	Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	06/13/2025
	BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	06/13/2025
	BVF Inc., By: /s/ Mark N. Lampert, President	06/13/2025
	/s/ Mark N. Lampert	06/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $OLMA alert in real time by email

Recent Analyst Ratings for

$OLMA

Date	Price Target	Rating	Analyst
4/2/2024	$24.00	Buy	Goldman
1/30/2024	$20.00	Buy	Citigroup
7/21/2023	$21.00	Outperform	Oppenheimer
5/5/2023	$16.00	Overweight	CapitalOne
2/22/2023	$12.00	Outperform	Credit Suisse
7/6/2022	$16.00	Buy	Canaccord Genuity
6/9/2022	$12.00	Neutral → Buy	H.C. Wainwright
2/28/2022		Neutral	HC Wainwright & Co.

More analyst ratings

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)

2. Transaction Date (Month/Day/Year)

2A. Deemed Execution Date, if any (Month/Day/Year)

3. Transaction Code (Instr. 8)

4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)

5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

7. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

Amount

(A) or (D)

Price

Common stock, $0.0001 par value⁽¹⁾

2,655,977

D⁽²⁾

Common stock, $0.0001 par value⁽¹⁾

2,003,966

D⁽³⁾

Common stock, $0.0001 par value⁽¹⁾

347,970

D⁽⁴⁾

Common stock, $0.0001 par value⁽¹⁾

99,556

I⁽⁵⁾

See footnote⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (Right to buy)⁽⁷⁾

$4.08

06/11/2025

24,150

⁽⁹⁾

06/11/2035

Common stock, $0.0001 par value

24,150

I⁽⁷⁾

See footnote⁽⁷⁾

Pre-Funded Warrant

$0.0001

⁽⁶⁾

Common stock, $0.0001 par value⁽¹⁾

3,291,004

D⁽²⁾

Pre-Funded Warrant

$0.0001

⁽⁶⁾

Common stock, $0.0001 par value⁽¹⁾

2,627,590

D⁽³⁾

Pre-Funded Warrant

$0.0001

⁽⁶⁾

Common stock, $0.0001 par value⁽¹⁾

336,288

D⁽⁴⁾

Stock Option (Right to buy)⁽⁷⁾

$12.36

⁽⁸⁾

06/14/2034

Common stock, $0.0001 par value

23,000

I⁽⁷⁾

See footnote⁽⁷⁾

Stock Option (Right to buy)⁽⁷⁾

$7.84

⁽⁸⁾

06/15/2033

Common stock, $0.0001 par value

21,520

I⁽⁷⁾

See footnote⁽⁷⁾

Stock Option (Right to buy)⁽⁷⁾

$3.61

⁽⁸⁾

06/16/2032

Common stock, $0.0001 par value

21,520

I⁽⁷⁾

See footnote⁽⁷⁾

Stock Option (Right to buy)⁽⁷⁾

$27.66

⁽⁸⁾

06/08/2031

Common stock, $0.0001 par value

21,520

I⁽⁷⁾

See footnote⁽⁷⁾

Stock Option (Right to buy)⁽⁷⁾

$19

⁽⁸⁾

11/17/2030

Common stock, $0.0001 par value

21,520

I⁽⁷⁾

See footnote⁽⁷⁾

Stock Option (Right to buy)⁽⁷⁾

$19

⁽⁸⁾

11/17/2030

Common stock, $0.0001 par value

21,520

I⁽⁷⁾

See footnote⁽⁷⁾

Stock Option (Right to buy)⁽⁷⁾

$19

⁽⁸⁾

11/17/2030

Common stock, $0.0001 par value

21,520

I⁽⁷⁾

See footnote⁽⁷⁾

Recent Analyst Ratings for

$OLMA

Date	Price Target	Rating	Analyst
4/2/2024	$24.00	Buy	Goldman
1/30/2024	$20.00	Buy	Citigroup
7/21/2023	$21.00	Outperform	Oppenheimer
5/5/2023	$16.00	Overweight	CapitalOne
2/22/2023	$12.00	Outperform	Credit Suisse
7/6/2022	$16.00	Buy	Canaccord Genuity
6/9/2022	$12.00	Neutral → Buy	H.C. Wainwright
2/28/2022		Neutral	HC Wainwright & Co.

More analyst ratings

SEC Form 4 filed by See Explanation of Responses Bvf Partners L P/Il

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $OLMA

SEC Form 4 filed by See Explanation of Responses Bvf Partners L P/Il

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $OLMA

$OLMA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Bain Capital Life Sciences Investors, Llc bought $1,727,370 worth of shares (300,000 units at $5.76) and disposed of 3,500,000 shares (SEC Form 4)

Amendment: Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) and bought $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)

Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)

$OLMA SEC Filings

Olema Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

Amendment: SEC Form SCHEDULE 13G/A filed by Olema Pharmaceuticals Inc.

SEC Form 10-Q filed by Olema Pharmaceuticals Inc.

$OLMA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by See Explanation of Responses Bvf Partners L P/Il

SEC Form 4 filed by Director Larson Yi

SEC Form 4 filed by Director Hrustanovic Gorjan

$OLMA Press Releases

Fastest customizable press release news feed in the world

$OLMA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

Goldman initiated coverage on Olema Pharmaceuticals with a new price target

Citigroup initiated coverage on Olema Pharmaceuticals with a new price target

Oppenheimer initiated coverage on Olema Pharmaceuticals with a new price target

$OLMA Leadership Updates

Live Leadership Updates

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

$OLMA Financials

Live finance-specific insights

$OLMA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Olema Pharmaceuticals Inc.

Recent Analyst Ratings for
$OLMA

Recent Analyst Ratings for
$OLMA

$OLMA
Insider Purchases

$OLMA
SEC Filings

$OLMA
Insider Trading

$OLMA
Press Releases

$OLMA
Analyst Ratings

$OLMA
Leadership Updates

$OLMA
Financials

$OLMA
Large Ownership Changes